|ZFIN ID: ZDB-PUB-191123-8|
Cellular rescue in a zebrafish model of congenital muscular dystrophy type 1A
Hall, T.E., Wood, A.J., Ehrlich, O., Li, M., Sonntag, C.S., Cole, N.J., Huttner, I.G., Sztal, T.E., Currie, P.D.
|Source:||NPJ Regenerative medicine 4: 21 (Journal)|
|Registered Authors:||Currie, Peter D., Ehrlich, Ophelia, Hall, Thomas, Huttner, Inken, Sonntag, Carmen, Sztal, Tamar Esther|
|PubMed:||31754462 Full text @ NPJ Regen Med|
Hall, T.E., Wood, A.J., Ehrlich, O., Li, M., Sonntag, C.S., Cole, N.J., Huttner, I.G., Sztal, T.E., Currie, P.D. (2019) Cellular rescue in a zebrafish model of congenital muscular dystrophy type 1A. NPJ Regenerative medicine. 4:21.
ABSTRACTLaminins comprise structural components of basement membranes, critical in the regulation of differentiation, survival and migration of a diverse range of cell types, including skeletal muscle. Mutations in one muscle enriched Laminin isoform, Laminin alpha2 (Lama2), results in the most common form of congenital muscular dystrophy, congenital muscular dystrophy type 1A (MDC1A). However, the exact cellular mechanism by which Laminin loss results in the pathological spectrum associated with MDC1A remains elusive. Here we show, via live tracking of individual muscle fibres, that dystrophic myofibres in the zebrafish model of MDC1A maintain sarcolemmal integrity and undergo dynamic remodelling behaviours post detachment, including focal sarcolemmal reattachment, cell extension and hyper-fusion with surrounding myoblasts. These observations imply the existence of a window of therapeutic opportunity, where detached cells may be "re-functionalised" prior to their delayed entry into the cell death program, a process we show can be achieved by muscle specific or systemic Laminin delivery. We further reveal that Laminin also acts as a pro-regenerative factor that stimulates muscle stem cell-mediated repair in lama2-deficient animals in vivo. The potential multi-mode of action of Laminin replacement therapy suggests it may provide a potent therapeutic axis for the treatment for MDC1A.